An Efficacy, Safety, and Tolerability Study of Canagliflozin in the Treatment of Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin Monotherapy

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 279 participants.

Also called NCT01340664

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 279 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT01340664
  • EudraCT 2010-024256-28
Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Canada, Czechia, Mexico, Romania, Russia, Slovakia (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01340664. Randomized; quadruple masking; primary purpose treatment. Start 2011-07 (registry gives no type); primary completion 2012-04 (actual). Results posted on 2014-09-01.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
An Efficacy, Safety, and Tolerability Study of Canagliflozin in the Treatment of Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin Monotherapy
Condition
Diabetes Mellitus, Type 2
Intervention (Drug)
Canagliflozin 50 mg
Intervention (Drug)
Placebo
Intervention (Drug)
Canagliflozin 150 mg
Intervention (Drug)
Metformin
Lead sponsor
Janssen Research & Development, LLC (class: industry)

Record details

Record id
cardio:ct-nct01340664
Content hash
63e05d4fccd133a03ca5dbe3792350b38aa26c0a3ce4d2554537f2c3cd9ffb1f